Post-vaccination analysis of anti-spike antibody responses in kidney transplant recipients with and without COVID-19 infection in a tertiary care centre, India

Jasuja, Sanjiv; Jha, Vivekanand; Sagar, Gaurav; Bahl, Anupam; Verma, Suman; Jasuja, Neharita; Kaur, Jasmeet

doi:10.1093/ckj/sfac057

Cited by 4 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kute et al reported 61.2% seroconversion in uninfected KTRs in an Indian cohort [ 17 ]. Similarly, Jasuja et al from India reported around 49% seroconversion in a similar cohort of uninfected KTRs [ 18 ]. This difference could be related to the variation in the study population or the diagnostic assay used to detect ARAb and neutralising antibodies in these studies.…”

Section: Discussionmentioning

confidence: 92%

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients

et al. 2022

View full text Add to dashboard Cite

Kidney transplant recipients (KTRs) are at a much higher risk of complications and death following COVID-19 and are poor vaccine responders. The data are limited on the immune response to Covishield® in KTRs. We prospectively recruited a cohort of 67 KTRs aged >18 between April 2021 and December 2021. Each participant was given two intramuscular doses of Covishield®, each of 0.5 mL, at an interval of 12 weeks. A blood specimen of 5.0 mL was collected from each participant at two points within a few days before administering the first dose of the vaccine and at any time between 4–12 weeks after administering the second dose. The sera were tested for anti-RBD antibody (ARAb) titre and neutralising antibody (NAb). An ACE2 competition assay was used as a proxy for virus neutralization. According to the prior COVID-19 infection, participants were grouped as (i) group A: prior symptomatic COVID-19 infection, (ii) group B: prior asymptomatic COVID-19 infection as evidenced by detectable ARAb in the prevaccination specimen, (iii) Group C: no prior infection with COVID-19, (iv) group D: Unclassified, i.e., participants had no symptoms suggestive of COVID-19, but their prevaccination specimen was not available for ARAb testing before vaccination. Fifty of sixty-seven participants (74.6%) provided paired specimens (group A 14, group B 27, and group C 9) and 17 participants (25.4%) provided only postvaccination specimens (group D). In the overall cohort (n = 67), 91% and 77.6% of participants developed ARAb and NAb, respectively. Their ARAb titre and NAb proportion were 2927 (520–7124) U/mL and 87.9 (24.4–93.2) %, respectively. Their median ARAb titre increased 65.6 folds, from 38.2 U/mL to 3137 U/mL. Similarly, the proportion of participants with NAb increased from 56% to 86%, and the NAb proportion raised 2.7 folds, from 23% to 91%. A comparison of vaccine response between the study groups showed that all those with or without prior COVID-19 infection showed a significant rise in ARAb titre (p < 0.05) and NAb proportion (p < 0.05) after the two doses of vaccine administration. The median value of folds rise in anti-RBD and NAb between groups A and B were comparable. Hence, ARAb is present in more than 3/4th of KTRs before the ChAdOx1 vaccine in India. The titer of ARAb and the proportion of NAb significantly increased after the two doses of the ChAdOx1 vaccine in KTRs.

show abstract

Section: Discussionmentioning

confidence: 92%

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients

et al. 2022

View full text Add to dashboard Cite

show abstract

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients

Bajpai,

Bose,

Saxena

et al. 2024

Vaccine

View full text Add to dashboard Cite

Antibody Response to Covishield and Covaxin in Kidney Transplant Recipients

Manhas,

Bansal,

Mahapatra

et al. 2024

IJN

View full text Add to dashboard Cite

Background The COVID-19 pandemic had a major impact on solid organ transplant recipients. COVID-19 vaccination plays a crucial role in pandemic management.There is limited data on replication-defective viral vectors [ChAdOx1-nCOV (COVISHIELDTM)] and whole inactivated one BBV-152 (COVAXINTM) in kidney transplant recipients (KTRs). This study aims to assess the humoral immune response and adverse effects of these vaccines in KTRs after the first and second doses of vaccination. Materials and Methods Anti-SARS-CoV-2 anti-spike antibody titers were measured in 285 KTRs recipients prior to vaccination, 3 weeks ± 3 days after first dose and 3 weeks ± 3 days after second dose of the COVISHIELD (n = 232) and COVAXIN (n = 55) vaccines. Anti-spike antibodies were measured by the chemiluminescence immunoassay method. The primary outcome was seroconversion after two doses of COVAXIN and COVISHIELD and secondary outcome was the incidence of adverse events to COVID-19 vaccines within one week of vaccination. Results At baseline, 25 (39.7%) and 67 (30.2%) of KTRs were found to be seropositive before receiving COVAXINTM and COVISHIELDTM, respectively. After first dose of vaccination, 46 (73.0%) and 158 (71.2%) were seropositive and after second dose, 51 (81.0%) and 177 (79.7%) were seropositive, respectively. Common adverse effects were fever, chills, myalgia, and headache which settled in 1–2 days. There was no episode of rejection. Conclusion Both ChAdOx1-nCOV and BBV-152 were well tolerated and induced robust antibody formation in KTRs in the Indian population.

show abstract

Post-vaccination analysis of anti-spike antibody responses in kidney transplant recipients with and without COVID-19 infection in a tertiary care centre, India

Cited by 4 publications

References 46 publications

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients

Antibody Response to Covishield and Covaxin in Kidney Transplant Recipients

Contact Info

Product

Resources

About